Gemini Bio

Gemini Bio

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12M

Overview

GeminiBio is a long-established, private company that serves as a critical supplier to the biotech and cell therapy industry. Its core business is divided into two verticals: Cell Culture Solutions, including its flagship Human AB Serum and various fetal bovine sera, and Process Liquid Solutions, centered on its GemPure™ line of high-purity water. The company's value proposition lies in providing essential, quality-controlled raw materials and custom formulations that streamline and de-risk the complex manufacturing processes for advanced therapies. With dedicated, segregated manufacturing facilities for animal-origin-free and animal-component products, GeminiBio is positioned as a specialized partner for scaling from bench to commercial launch (BLA).

DiagnosticsDrug Delivery

Technology Platform

Specialized manufacturing platform for biological sera (Human AB, FBS) and high-purity process liquids (WFI-quality water, custom buffers/media). Features segregated cGMP facilities (animal-origin-free and animal-component), aseptic assurance systems, and compliance with pharmacopeial standards (USP/EP/JP).

Funding History

2
Total raised:$12M
Series A$10M
Seed$2M

Opportunities

Strong growth driven by the expanding cell and gene therapy market, which heavily relies on high-quality human and xeno-free components.
Increasing industry trend to outsource non-core manufacturing steps like media and buffer preparation presents a significant service expansion opportunity.
Regulatory emphasis on animal-origin-free and defined components aligns perfectly with the company's dedicated AOF facility and product strategy.

Risk Factors

Vulnerability to supply chain disruptions for critical raw materials like human and animal blood products.
Revenue is tied to the funding and success of biotech clients, making it susceptible to sector downturns.
Intense competition from large, diversified life science suppliers and the risk of customers internalizing manufacturing processes.

Competitive Landscape

Competes with large, integrated life science tools companies (e.g., Thermo Fisher Scientific, Merck KGaA, Sartorius) that offer broad portfolios of cell culture media and bioprocessing supplies. Also faces competition from other specialized serum and media suppliers (e.g., Cytiva, Bio-Techne, Seracare). Differentiation is achieved through deep specialization in Human AB Serum, segregated manufacturing facilities, and a strong focus on custom, GMP-grade solutions for cell therapy.